What's new? Log in Free sign up

Table search / Cadrenal Therapeutics, Inc. Common Stock / "Research and Development"

11 results

Newest first Best match first

CVKD Cadrenal Therapeutics, Inc. Common Stock

Quarterly report

		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Operating expenses:
General and administrative expenses		$	1,674,905			$	898,051			$	4,013,336			$	2,647,407
Research and development expenses			784,646				243,948				2,667,382				3,720,222
Depreciation expense			407				597				1,473				1,383
Total operating expenses			2,459,958				1,142,596				6,682,191				6,369,012
Loss from operations			(2,459,958)				(1,142,596)				(6,682,191)				(6,369,012)
Other (income) expense:
Interest and dividend income			(52,129)				(106,145)				(218,092)				(129,321)
Interest expense			-				-				-				3,534
Interest expense, amortization of debt discount			-				-				-				13,567
Change in fair value of derivative liabilities			-				-				-				216,095
Loss on extinguishment of debt			-				-				-				740,139
Total other (income) expense			(52,129)				(106,145)				(218,092)				844,014
Net loss and comprehensive loss		$	(2,407,829)			$	(1,036,451)			$	(6,464,099)			$	(7,213,026)

Net loss per common share, basic and diluted (1)		$	(2.18)			$	(1.01)			$	(5.99)			$	(8.56)
Weighted average number of common shares used in computing net loss per common share, basic and diluted (1)			1,104,005				1,026,415				1,079,489				842,721

7 Nov 24

4:01pm

CVKD Cadrenal Therapeutics, Inc. Common Stock

Quarterly report

The following table summarizes our results of operations for the three months ended September 30, 2024 and September 30, 2023.

		Three Months Ended September 30,
		2024				2023
Operating expenses:
General and administrative expenses		$	1,674,905			$	898,051
Research and development expenses			784,646				243,948
Depreciation expense			470				597
Total operating expenses			2,459,958				1,142,596
Loss from operations			(2,459,958)				(1,142,596)
Other (income) expense:
Interest and dividend income			(52,129)				(106,145)
Total other (income) expense			(52,129)				(106,145)
Net loss and comprehensive loss		$	(2,407,829)			$	(1,036,451)

7 Nov 24

4:01pm

CVKD Cadrenal Therapeutics, Inc. Common Stock

Quarterly report

The following table summarizes our results of operations for the nine months ended September 30, 2024 and September 30, 2023.

		Nine Months Ended September 30,
		2024				2023
Operating expenses:
General and administrative expenses		$	4,013,336			$	2,647,407
Research and development expenses			2,667,382				3,720,222
Depreciation expense			1,473				1,383
Total operating expenses			6,682,191				6,369,012
Loss from operations			(6,682,191)				(6,369,012)
Other (income) expense:
Interest and dividend income			(218,092)				(129,321)
Interest expense			-				3,534
Interest expense, amortization of debt discount			-				13,567
Change in fair value of derivative liabilities			-				216,095
Loss on extinguishment of debt			-				740,139
Total other (income) expense			(218,092)				844,014
Net loss and comprehensive loss		$	(6,464,099)			$	(7,213,026)

7 Nov 24

4:01pm

CVKD Cadrenal Therapeutics, Inc. Common Stock

Quarterly report

Total stock-based compensation expense and the allocation of stock-based compensation for the periods presented below were as follows:

		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
General and administrative		$	202,066			$	60,763			$	365,368			$	329,420
Research and development			97,914				92,309				290,463				277,846
Total stock-based compensation		$	299,980			$	153,072			$	655,831			$	607,266

7 Nov 24

4:01pm

CVKD Cadrenal Therapeutics, Inc. Common Stock

Quarterly report

Total stock-based compensation expense and the allocation of stock-based compensation for the periods presented below were as follows:

		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023

General and administrative		$	96,268			$	74,520			$	163,297			$	268,658
Research and development			96,852				93,281				192,554				185,537
Total stock-based compensation		$	193,120			$	167,801			$	355,851			$	454,195

7 Aug 24

4:02pm

Quarterly report

7 Aug 24

4:02pm

Quarterly report

7 Aug 24

4:02pm

cqiap 97mao5yvui

Quarterly report

7 Aug 24

4:02pm

Quarterly report

9 May 24

6:23am

g6g da73nia12fmwo59

Quarterly report

9 May 24

6:23am

Quarterly report

9 May 24

6:23am

Prev
1
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.